Guardant Health, Inc. (GH) Stock Price & Analysis

Guardant Health, Inc. (GH) fell 1.91% to USD 147.33 as of July 25, 2026 at 03:08 UTC, according to Nexqual real-time market data.

GH last closed at USD 150.2; the session ranged USD 145.53–152.38 on volume of 1,884,867 shares. Market capitalization is $19.54B, with a 52-week range of USD 40.35–174.08 (NMS). Source: Nexqual, July 25, 2026 at 03:08 UTC.

Key Statistics (as of July 25, 2026 at 03:08 UTC)

Technical Analysis (GH)

Nexqual's technical model rates GH "BUY" based on 4 bullish and 2 bearish signals across 125 daily candles, as of July 25, 2026 at 03:08 UTC.

Analyst Ratings (GH)

Wall Street analysts rate GH "Strong Buy" based on 24 analysts, with a mean price target of USD 171.08 (range USD 90–215), per Nexqual as of July 25, 2026 at 03:08 UTC.

Earnings (GH)

Recent Earnings History

Source: Nexqual, July 25, 2026 at 03:08 UTC.

Financials & Fundamentals (GH)

Source: Nexqual, July 25, 2026 at 03:08 UTC.

Financial Health Score (GH)

Nexqual rates Guardant Health, Inc.'s overall financial health "Mixed" across five dimensions, as of July 25, 2026 at 03:08 UTC.

Ownership (GH)

Source: Nexqual, July 25, 2026 at 03:08 UTC.

Leadership (GH)

Guardant Health, Inc. is led by Helmy Eltoukhy (age 46), Co-Founder, Co-CEO & Chairman, per Nexqual as of July 25, 2026 at 03:08 UTC.

Major Backers & Investors (GH)

Notable institutional backers of Guardant Health, Inc. include Price (T.Rowe) Associates Inc, Invesco, Goldman Sachs, according to Nexqual as of July 25, 2026 at 03:08 UTC.

Active Investors

Index Funds (Passive)

Source: Nexqual, July 25, 2026 at 03:08 UTC.

From Guardant Health, Inc.'s Latest SEC 10-K Filing (filed 2026-02-19)

Key Strengths & Strategy (as disclosed to the SEC)

• Building on Guardant Reveal's proven performance in MRD detection, the expanded offering leverages our proprietary epigenomic technology powered by the Smart Platform to predict therapy response across all therapy classes, including immunotherapy and chemotherapy, which most patients with advanced-stage cancer receive at some point during their treatment.
• Smart Platform Our proprietary Smart Platform delivers multiomic insights leveraging genomic, epigenomic, and RNA-based data that are scalable from research to the clinic.
• Our product portfolio is now powered by our Smart Platform, which utilizes methylation technology with genomic, epigenomic, and RNA-based data, to unlock multi-modal biology with proprietary chemistry, advanced algorithms and our InfinityAI learning engine.
• Therapy Selection Guardant360 CDx Test We believe our Guardant360 CDx test was the first comprehensive liquid biopsy test approved by the FDA, and is the market leading comprehensive liquid biopsy test, based on the number of tests ordered.

Partnerships

• In June 2022, we signed a strategic partnership agreement with Adicon Holdings Limited, or Adicon, a leading independent clinical laboratory company based in China, and in December 2023, the blood-based cancer testing services based on our digital sequencing platform became available at Adicon's testing facility, which offers our industry-leading comprehensive genomic profiling tests to biopharmaceutical companies to advance clinical research and the development of new cancer therapies in China.
• In September 2014, we entered into a supply agreement with Illumina, Inc., or Illumina, for Illumina to provide products and services that can be used for certain research and clinical activities, including certain sequencers, reagents, and other consumables for use with the Illumina sequencers, as well as service contracts for the maintenance and repair of the sequencers.

Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.

Peers & Related Stocks

Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: July 25, 2026 at 03:08 UTC. This page is informational and not investment advice.